You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Colorcon
Baxter
Harvard Business School
AstraZeneca

Last Updated: February 18, 2020

DrugPatentWatch Database Preview

Patent: 6,232,094

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,232,094
Title: DNA encoding human .kappa. casein and process for obtaining the protein
Abstract:The present invention relates to an expression system comprising a DNA sequence encoding a polypeptide which has a biological activity of human .kappa.-casein, the system comprising a 5\'-flanking sequence capable of mediating expression of said DNA sequence. In preferred embodiments the 5\'-flanking sequence is from a milk protein gene of a mammal such as a casein gene or whey acidic protein (WAP) gene and the DNA sequence contains at least one intron sequence selected from the intron sequences presented in SEQ ID NO:30. The invention also relates to DNA sequences, replicable expression vectors and cells harboring said vectors, recombinant polypeptide e.g. in glycosylated form, and milk, infant formula or nutrient supplement comprising recombinant polypeptide. The invention further relates to a transgenic non-human mammal such as a mouse, rat, rabbit, goat, sheep, pig, lama, camel or bovine species whose germ cells and somatic cells contain a DNA sequence as defined above as a result of chromosomal incorporation into the non-human mammalian genome, or into the genome of an ancestor of said non-human mammal.
Inventor(s): Hansson; Lennart (Umea, SE), Stromqvist; Mats (Umea, SE), Bergstrom; Sven (Umea, SE), Hernell; Olle (Umea, SE), Tornell; Jan (Vastra Frolunda, SE)
Assignee: Symbicom Aktiebolag (Umea, SE)
Application Number:08/462,437
Patent Claims:see list of patent claims

Details for Patent 6,232,094

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Symbicom Aktiebolag (Umea, SE) 2018-05-15 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Symbicom Aktiebolag (Umea, SE) 2018-05-15 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Symbicom Aktiebolag (Umea, SE) 2018-05-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Harvard Business School
Baxter
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.